Head to head
Enhance.MD vs NovoCare Pharmacy: Pricing, Evidence and What Neither Discloses
We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $149 against $169 compares a price paid for about four weeks with one that may not hold either.
We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $149 against $169 compares a price paid for about four weeks with one that may not hold either. Both providers' undisclosed fields are shown below rather than omitted, and neither has named its fulfilling pharmacy to us.
The short answer
We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $149 against $169 compares a price paid for about four weeks with one that may not hold either. Both figures are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What neither has told us
Neither Enhance.MD nor NovoCare Pharmacy has named its fulfilling pharmacy or its registration class. That is true of every provider in our dataset, and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | Enhance.MD | NovoCare Pharmacy |
|---|---|---|
| Tirzepatide | $169 | not captured |
| Semaglutide | $212 | $149 |
| Field | Enhance.MD | NovoCare Pharmacy |
|---|---|---|
| Lowest captured all-in | $169/mo | $149/mo |
| Lowest tirzepatide | $169/mo | — |
| Lowest semaglutide | $212/mo | $149/mo |
| Records we hold | 3 | 2 |
| Evidence status | Provider-reported Reported | Provider-reported Reported |
| Fulfilling pharmacy named to us | no | no |
| Registration class disclosed | no | no |
| State availability verified | no | no |
| Cancellation terms captured | — | — |
A dash means no figure held. How we grade evidence.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| NovoCare Pharmacy | manufacturer_direct | brand oral, FDA-approved | — | $149 | — | $149 | Recurring | Reported | 2026-07-06 |
| Enhance.MD | prepaid | compounded microdose | — | $169 | — | $169 | Commitment tier | Reported | 2026-07-06 |
| Enhance.MD | prepaid | compounded injectable | — | $212 | — | $212 | Commitment tier | Reported | 2026-07-06 |
| Enhance.MD | prepaid | compounded injectable | — | $280 | — | $280 | Commitment tier | Reported | 2026-07-06 |
| NovoCare Pharmacy | manufacturer_direct | brand injectable, FDA-approved | — | $349 | — | $349 | Advertised starting | Reported | 2026-07-06 |
NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).
Questions readers actually ask
Is Enhance.MD cheaper than NovoCare Pharmacy?
We will not name a cheaper provider here. At least one of these figures is an advertised starting price or is reported to rise with dose, so $149 against $169 compares a price paid for about four weeks with one that may not hold either.
Have you captured either Enhance.MD or NovoCare Pharmacy pricing?
No. Both figures here are provider claims we have not confirmed at source, so treat the direction as indicative and the amounts as unconfirmed.
Does Enhance.MD or NovoCare Pharmacy name its compounding pharmacy?
Neither. Two providers in our dataset do, and this is the field our rubric weights most heavily, so neither can score above 45 of 100.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- NexLife vs FoundComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
Related coverage
Tirzepatide Ranked. “Enhance.MD vs NovoCare Pharmacy: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/enhance-md-vs-novocare/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.